ATE514427T1 - Oligonukleotide kombiniert mit rapamycin zur behandlung von krebs - Google Patents

Oligonukleotide kombiniert mit rapamycin zur behandlung von krebs

Info

Publication number: ATE514427T1
Authority: AT; Austria
Prior art keywords: rapamycin; treat cancer; oligonucleotide combined; tumors; oligonucleotide
Prior art date: 2005-03-03

Application number

AT07117228T

Other languages

English (en)

Inventor

Massimo Iacobelli

Gunter Eissner

Laura Iris Ferro

Original Assignee

Gentium Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-03

Filing date

2006-02-27

Publication date

2011-07-15

2006-02-27 Application filed by Gentium Spa filed Critical Gentium Spa

2011-07-15 Application granted granted Critical

2011-07-15 Publication of ATE514427T1 publication Critical patent/ATE514427T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 3
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 2
229960002930 sirolimus Drugs 0.000 title abstract 2
108091034117 Oligonucleotide Proteins 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
208000034578 Multiple myelomas Diseases 0.000 abstract 1
206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 abstract 1
230000033115 angiogenesis Effects 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
201000008275 breast carcinoma Diseases 0.000 abstract 1
229960004120 defibrotide Drugs 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
238000000605 extraction Methods 0.000 abstract 1
229940124276 oligodeoxyribonucleotide Drugs 0.000 abstract 1
210000000056 organ Anatomy 0.000 abstract 1
235000013311 vegetables Nutrition 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT07117228T 2005-03-03 2006-02-27 Oligonukleotide kombiniert mit rapamycin zur behandlung von krebs ATE514427T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT000336A ITMI20050336A1 (it)	2005-03-03	2005-03-03	Formulazione ad attivita' anti-tumorale
US73140405P	2005-10-28	2005-10-28

Publications (1)

Publication Number	Publication Date
ATE514427T1 true ATE514427T1 (de)	2011-07-15

Family

ID=39085989

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07117228T ATE514427T1 (de)	2005-03-03	2006-02-27	Oligonukleotide kombiniert mit rapamycin zur behandlung von krebs

Country Status (9)

Country	Link
EP (1)	EP1867335B1 (de)
CN (3)	CN101123973A (de)
AT (1)	ATE514427T1 (de)
BR (2)	BRPI0607833A2 (de)
DK (1)	DK1867335T3 (de)
ES (1)	ES2366486T3 (de)
IT (1)	ITMI20050336A1 (de)
PT (1)	PT1867335E (de)
ZA (1)	ZA200707417B (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1252174B (it)	1991-12-09	1995-06-05	Crinos Industria Farmaco	Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
AU754242B2 (en) *	1997-04-28	2002-11-07	Arsinur Burcoglu	Method of treating HIV infection and related secondary infections thereof
WO1998054313A2 (en) *	1997-05-30	1998-12-03	Mcgill University	Dna methyltransferase genomic sequences and antisense oligonucleotides
DE19740384A1 (de) *	1997-09-08	1999-03-11	Max Delbrueck Centrum	Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN

2005
- 2005-03-03 IT IT000336A patent/ITMI20050336A1/it unknown
2006
- 2006-02-27 BR BRPI0607833A patent/BRPI0607833A2/pt not_active IP Right Cessation
- 2006-02-27 ES ES07117228T patent/ES2366486T3/es not_active Expired - Lifetime
- 2006-02-27 CN CNA2006800055559A patent/CN101123973A/zh active Pending
- 2006-02-27 CN CNA2008100822369A patent/CN101254204A/zh active Pending
- 2006-02-27 DK DK07117228.2T patent/DK1867335T3/da active
- 2006-02-27 PT PT07117228T patent/PT1867335E/pt unknown
- 2006-02-27 BR BRPI0608259A patent/BRPI0608259A2/pt not_active IP Right Cessation
- 2006-02-27 AT AT07117228T patent/ATE514427T1/de active
- 2006-02-27 EP EP07117228A patent/EP1867335B1/de not_active Expired - Lifetime
- 2006-02-27 CN CNA2006800065739A patent/CN101232892A/zh active Pending
- 2006-02-27 ZA ZA200707417A patent/ZA200707417B/xx unknown

Also Published As

Publication number	Publication date
CN101254204A (zh)	2008-09-03
PT1867335E (pt)	2011-09-06
CN101232892A (zh)	2008-07-30
EP1867335A2 (de)	2007-12-19
EP1867335B1 (de)	2011-06-29
ITMI20050336A1 (it)	2006-09-04
BRPI0608259A2 (pt)	2016-10-11
DK1867335T3 (da)	2011-08-01
BRPI0607833A2 (pt)	2017-05-30
ZA200707417B (en)	2008-12-31
CN101123973A (zh)	2008-02-13
ES2366486T3 (es)	2011-10-20
EP1867335A3 (de)	2008-03-12

Similar Documents

Publication	Publication Date	Title
Kapinova et al.	2017	Are plant-based functional foods better choice against cancer than single phytochemicals? A critical review of current breast cancer research
MX361467B (es)	2018-12-06	Compuestos de isoindolina para uso en el tratamiento de cancer.
MX2010009670A (es)	2010-09-22	Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
EA200901074A1 (ru)	2010-04-30	Лечение метастатической стадии рака предстательной железы дегареликсом
ES2426938T8 (es)	2018-08-23	Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para tratar cánceres humanos
BR112019023409A2 (pt)	2020-06-16	Métodos para tratar um câncer em um paciente e uma malignidade hematológica, para expandir linfócitos infiltrantes de tumor, linfócitos de sangue periférico e linfócitos infiltrantes de medula, processo para a preparação de uma população de linfócitos infiltrantes de tumor, e, uso de um tumor líquido na fabricação de uma população de linfócitos infiltrantes de tumor.
MX346924B (es)	2017-04-05	Compuestos de diarilhidantoina.
MX354099B (es)	2018-02-13	Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
MX2015000821A (es)	2015-12-08	Compuestos para inmunoterapia dirigida.
DE602004015064D1 (de)	2008-08-28	Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
DOP2011000199A (es)	2011-10-15	Compuestos heterociclocos y metodos de uso
MX342250B (es)	2016-09-22	Tratamiento de cánceres resistentes a antagonistas notch1, mediante el uso de antagonistas notch3.
EA201200473A1 (ru)	2012-10-30	Замещенные (гетероарилметил)тиогидантоины
MX2007010407A (es)	2007-10-17	Formulacion con accion anti-tumor.
EP4520745A3 (de)	2025-05-14	Doppelt gerichtete konstrukte zur beeinflussung der tumorkillierung
WO2009105457A3 (en)	2009-12-30	Slit2 cancer markers
WO2010074936A3 (en)	2010-09-16	Enzastaurin for the treatment of cancer
ATE527998T1 (de)	2011-10-15	Illudin-analoga als krebsmittel
WO2007134132A8 (en)	2008-09-04	Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
ATE514427T1 (de)	2011-07-15	Oligonukleotide kombiniert mit rapamycin zur behandlung von krebs
WO2013066485A3 (en)	2014-09-04	Compositions and methods for treatment of metastatic cancer
WO2007033167A3 (en)	2007-10-18	Compositions and methods for detecting and treating cancer
WO2007070725A3 (en)	2007-08-02	Device producing and use of microwave energy for thermotherapy
WO2007139985A3 (en)	2008-07-31	Cooperating oncogenes in cancer
WO2012006563A3 (en)	2012-06-14	Novel daidzein analogs as treatment for cancer

Legal Events

Date

Code

Title

Description

2012-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1867335

Country of ref document: EP